<table width="80%" xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 2 Dose to Body Weight Range to Achieve Similar Steady-State Exposure (AUC<sub>0–24hr</sub>) to unbound Oxaprozin in JRA Patients Relative to 70 kg Adult Rheumatoid Arthritis Patients Administered Oxaprozin 1200 mg QD<footnote>Model-based nomogram derived from unbound oxaprozin steady-state drug plasma concentrations of JRA patients weighing 22.1 to 42.7 kg or ≥45.0 kg administered oxaprozin 600 mg or 1200 mg QD for 14 days, respectively.</footnote>
</caption>
<col align="center" width="40%"></col>
<col align="center" width="40%"></col>
<thead>
<tr>
<th align="center">Dose (mg)</th>
<th align="center">Body WeightRange (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>600</td>
<td>22 –31</td>
</tr>
<tr>
<td stylecode="Toprule">900</td>
<td stylecode="Toprule">32 –54</td>
</tr>
<tr>
<td stylecode="Toprule">1200</td>
<td stylecode="Toprule">≥ 55</td>
</tr>
</tbody>
</table>